A Clinical Study of Immune Globulin Subcutaneous (Human), 20% Solution (IGSC, 20%) for the Evaluation of Efficacy, Safety, Tolerability and Pharmacokinetics in Subjects With Primary Immunodeficiency Diseases (PIDD)

Trial Profile

A Clinical Study of Immune Globulin Subcutaneous (Human), 20% Solution (IGSC, 20%) for the Evaluation of Efficacy, Safety, Tolerability and Pharmacokinetics in Subjects With Primary Immunodeficiency Diseases (PIDD)

Completed
Phase of Trial: Phase II/III

Latest Information Update: 06 Mar 2017

At a glance

  • Drugs Immune globulin (Primary)
  • Indications Immunodeficiency disorders
  • Focus Therapeutic Use
  • Sponsors Baxalta
  • Most Recent Events

    • 06 Mar 2017 Results assessing treatment satisfaction in patients from two phase 2/3 studies (European study and North American study) presented at the 2017 Annual Meeting of the American Academy of Allergy, Asthma and Immunology
    • 06 Mar 2017 Results (n=39) of combined safety and tolerability data in pediatric patients form two phase 2/3 studies (257242 and 278874), presented at the 2017 Annual Meeting of the American Academy of Allergy, Asthma and Immunology
    • 06 Mar 2017 Results (n=112) assessing safety and tolerability using patient data from two phase 2/3 studies (257242 and 278874), presented at the 2017 Annual Meeting of the American Academy of Allergy, Asthma and Immunology
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top